MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jansen, G.
Right arrow Articles by Assaraf, Y. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jansen, G.
Right arrow Articles by Assaraf, Y. G.

Vol. 55, Issue 4, 761-769, April 1999

Multiple Mechanisms of Resistance to Polyglutamatable and Lipophilic Antifolates in Mammalian Cells: Role of Increased Folylpolyglutamylation, Expanded Folate Pools, and Intralysosomal Drug Sequestration

Gerrit Jansen, Haim Barr, Ietje Kathmann, Marlene A. Bunni, David G. Priest, Paul Noordhuis, Godefridus J. Peters, and Yehuda G. Assaraf

Department of Oncology, Section of Biochemical Pharmacology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands (G.J., I.K., P.N., G.J.P.); Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina (M.A.B., D.G.P.); and Department of Biology, The Technion, Israel Institute of Technology, Haifa, Israel (H.B., Y.G.A.)

Chinese hamster ovary PyrR100 cells display more than 1000-fold resistance to pyrimethamine (Pyr), a lipophilic antifolate inhibitor of dihydrofolate reductase. PyrR100 cells had wild-type DHFR activity, lost folate exporter activity, and had a 4-fold increased activity of a low pH folic acid transporter. Here we report on the marked alterations identified in PyrR100 cells compared with parental cells: 1) ~100-fold decreased folic acid growth requirement; 2) a 25-fold higher glucose growth requirement in Pyr-containing medium; 3) a 2.5- to 4.1-fold increase in folylpolyglutamate synthetase activity; 4) a 3-fold increase in the accumulation of [3H]folic acid and a 3-fold expansion of the intracellular folate pools; 5) a 4-fold increase in the activity of the lysosomal marker beta -hexoseaminidase, suggesting an increased lysosome number/PyrR100 cell; and 6) a small reduction in the steady-state accumulation of [3H]Pyr and no evidence of catabolism or modification of cellular [3H]Pyr. Consequently, PyrR100 cells were markedly resistant to the lipophilic antifolates trimetrexate (40-fold) and AG377 (30-fold) and to the polyglutamatable antifolates 5,10-Dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF) (26-fold) and AG2034 (14-fold). Resistance to these drugs was reversed in PyrR100 cells transferred into folate-depleted medium. In conclusion, these multiple resistance factors collectively result in a prominent increase in folate accumulation, an expansion of the intracellular folylpolyglutamate pool, and abolishment of the cytotoxic activity of polyglutamatable and lipophilic antifolates. The role of increased lysosome number per cell in sequestration of hydrophobic weak base drugs such as Pyr is also discussed as a novel mechanism of drug resistance.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
R. C. Cho, P. D. Cole, K.-J. Sohn, G. Gaisano, R. Croxford, B. A. Kamen, and Y.-I. Kim
Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells
Mol. Cancer Ther., November 1, 2007; 6(11): 2909 - 2920.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Zhao, S. Chattopadhyay, M. Hanscom, and I. D. Goldman
Antifolate Resistance in a HeLa Cell Line Associated With Impaired Transport Independent of the Reduced Folate Carrier
Clin. Cancer Res., December 15, 2004; 10(24): 8735 - 8742.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
K-J Sohn, F Smirnakis, D N Moskovitz, P Novakovic, Z Yates, M Lucock, R Croxford, and Y-I Kim
Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate
Gut, December 1, 2004; 53(12): 1825 - 1831.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. Ifergan, A. Shafran, G. Jansen, J. H. Hooijberg, G. L. Scheffer, and Y. G. Assaraf
Folate Deprivation Results in the Loss of Breast Cancer Resistance Protein (BCRP/ABCG2) Expression: A ROLE FOR BCRP IN CELLULAR FOLATE HOMEOSTASIS
J. Biol. Chem., June 11, 2004; 279(24): 25527 - 25534.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Stark, L. Rothem, G. Jansen, G. L. Scheffer, I. D. Goldman, and Y. G. Assaraf
Antifolate Resistance Associated with Loss of MRP1 Expression and Function in Chinese Hamster Ovary Cells with Markedly Impaired Export of Folate and Cholate
Mol. Pharmacol., August 1, 2003; 64(2): 220 - 227.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. L. van der Wilt, H. H. J. Backus, K. Smid, L. Comijn, G. Veerman, D. Wouters, D. A. Voorn, D. G. Priest, M. A. Bunni, F. Mitchell, et al.
Modulation of Both Endogenous Folates and Thymidine Enhance the Therapeutic Efficacy of Thymidylate Synthase Inhibitors
Cancer Res., May 1, 2001; 61(9): 3675 - 3681.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
E. L. Volk, K. Rohde, M. Rhee, J. J. McGuire, L. A. Doyle, D. D. Ross, and E. Schneider
Methotrexate Cross-Resistance in a Mitoxantrone-selected Multidrug-resistant MCF7 Breast Cancer Cell Line Is Attributable to Enhanced Energy-dependent Drug Efflux
Cancer Res., July 1, 2000; 60(13): 3514 - 3521.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
H. L. McLeod, J. Cassidy, R. H. Powrie, D. G. Priest, M. A. Zorbas, T. W. Synold, S. Shibata, D. Spicer, D. Bissett, Y. K. Pithavala, et al.
Pharmacokinetic and Pharmacodynamic Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitor AG2034
Clin. Cancer Res., July 1, 2000; 6(7): 2677 - 2684.
[Abstract] [Full Text]

Home page
 JNCI J Natl Cancer InstHome page
F. M. Sirotnak
RESPONSE: Re: Folylpolyglutamyl Synthetase Gene Transfer and Glioma Antifolate Sensitivity in Culture and In Vivo
J Natl Cancer Inst, December 1, 1999; 91(23): 2049 - 2050.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. Jansen, G. J. Peters, H. M. Pinedo, D. G. Priest, and Y. G. Assaraf
Re: Folylpolyglutamyl Synthetase Gene Transfer and Glioma Antifolate Sensitivity in Culture and In Vivo
J Natl Cancer Inst, December 1, 1999; 91(23): 2047a - 2048a.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
G. J. Peters, E. Smitskamp-Wilms, K. Smid, H. M. Pinedo, and G. Jansen
Determinants of Activity of the Antifolate Thymidylate Synthase Inhibitors Tomudex (ZD1694) and GW1843U89 against Mono- and MultilayeredColon Cancer Cell Lines under Folate-restricted Conditions
Cancer Res., November 1, 1999; 59(21): 5529 - 5535.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. H. Hooijberg, H. J. Broxterman, M. Kool, Y. G. Assaraf, G. J. Peters, P. Noordhuis, R. J. Scheper, P. Borst, H. M. Pinedo, and G. Jansen
Antifolate Resistance Mediated by the Multidrug Resistance Proteins MRP1 and MRP2
Cancer Res., June 1, 1999; 59(11): 2532 - 2535.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Drori, G. Jansen, R. Mauritz, G. J. Peters, and Y. G. Assaraf
Clustering of Mutations in the First Transmembrane Domain of the Human Reduced Folate Carrier in GW1843U89-resistant Leukemia Cells with Impaired Antifolate Transport and Augmented Folate Uptake
J. Biol. Chem., September 29, 2000; 275(40): 30855 - 30863.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics